D
Dishman Carbogen
Biotechnology · DCAL
Small CapHealthcareDistressed / Turnaround
Arpit J. Vyas
Global Managing Director · Visionary
Company DNA
Performance-Driven
About
Dishman Carbogen is a Small Cap company in the Healthcare sector, listed on NSE as DCAL. With a market cap of ₹3K Cr and revenue of ₹3K Cr, it is currently in the Distressed / Turnaround phase. Known for its Performance-Driven culture and Fast-Follower approach to innovation, the company operates at a Seasonal-Burst pace. Global operations in the biotechnology R&D sector necessitate a focus on scientific outcomes and high-pressure project deadlines. Its strategic mandate: The company faces significant leverage challenges and margin pressure that require a focus on balance sheet stability over aggressive growth.
FAQ
What kind of company is Dishman Carbogen?
Dishman Carbogen is a Small Cap Healthcare company (DCAL) in the Distressed / Turnaround phase with a market cap of ₹3K Cr. It is classified as Performance-Driven in culture.
What is Dishman Carbogen's culture and work environment like?
Dishman Carbogen has a Performance-Driven culture with Fast-Follower innovation DNA and a Seasonal-Burst pace of execution. Employee brand: Demanding Machine. Customer relationship style: B2B-Enterprise. Global operations in the biotechnology R&D sector necessitate a focus on scientific outcomes and high-pressure project deadlines.
Who leads Dishman Carbogen?
Dishman Carbogen is led by Arpit J. Vyas (Global Managing Director), a Visionary leader with 20 years of experience.
What are Dishman Carbogen's financials?
Dishman Carbogen reported revenue of ₹3K Cr in FY25 with a 5-year revenue CAGR of 8.5%. Operating margin: 5.5%. Market cap: ₹3K Cr.
Culture & Strategy
CulturePerformance-Driven
InnovationFast-Follower
PaceSeasonal-Burst
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployeeDemanding Machine
BrandTechnical-Expert
LifecycleDistressed / Turnaround
Global operations in the biotechnology R&D sector necessitate a focus on scientific outcomes and high-pressure project deadlines.
Mandate
The company faces significant leverage challenges and margin pressure that require a focus on balance sheet stability over aggressive growth.
The company faces significant leverage challenges and margin pressure that require a focus on balance sheet stability over aggressive growth.
Financials
Revenue FY25₹3K Cr
PAT FY25₹3 Cr
Rev CAGR 5Y8.5%
OPM5.5%
NPM0.1%
ROE0.1%
ROCE1.8%
P/E21
Fwd P/E12.7
P/B0.4
D/E40.2
Mkt Cap₹3K Cr
Promoter69.3%
Institutional2.4%
Similar Culture
Could You Lead Dishman Carbogen?
Take the Genome Benchmark →